Artal Group Sa Has Decreased Its Alnylam Pharmaceuticals INC (Call) (ALNY) Holding by $6.35 Million; Share Value Rose

May 25, 2018 - By Vivian Park

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) LogoInvestors sentiment increased to 2.03 in Q4 2017. Its up 1.11, from 0.92 in 2017Q3. It increased, as 27 investors sold ALNY shares while 47 reduced holdings. 67 funds opened positions while 83 raised stakes. 90.18 million shares or 4.83% more from 86.02 million shares in 2017Q3 were reported. Aqr Capital Mgmt Limited Liability Company holds 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 6,545 shares. Northern Trust holds 0.02% or 474,609 shares in its portfolio. Aperio Grp Llc owns 21,078 shares. 12 West Cap Mngmt Limited Partnership holds 10.75% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 700,000 shares. Royal Bancshares Of Canada has 2,687 shares for 0% of their portfolio. Amp Cap Invsts Ltd invested 0.02% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Prudential holds 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 4,704 shares. Renaissance Tech Ltd Liability holds 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 8,100 shares. Quantitative Investment Mgmt Ltd Co stated it has 0.01% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Blackrock accumulated 7.12 million shares or 0.04% of the stock. Commercial Bank Of New York Mellon holds 395,267 shares. 1,826 were reported by Bluemountain Cap Mgmt Ltd. Ohio-based Meeder Asset Mngmt Inc has invested 0.03% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Point72 Asset Management Limited Partnership invested 0.05% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Mitsubishi Ufj has invested 0.1% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Since January 4, 2018, it had 0 insider purchases, and 10 insider sales for $38.04 million activity. Shares for $4.17 million were sold by SCHIMMEL PAUL on Tuesday, March 13. On Tuesday, March 13 the insider Ausiello Dennis A sold $2.57 million. 1,562 shares were sold by KEATING LAURIE, worth $234,033 on Tuesday, March 20. Shares for $2.24M were sold by SHARP PHILIP A. $12.67 million worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares were sold by Vaishnaw Akshay. Shares for $985,958 were sold by Greenstreet Yvonne.

Artal Group Sa decreased its stake in Alnylam Pharmaceuticals Inc (Call) (ALNY) by 20% based on its latest 2017Q4 regulatory filing with the SEC. Artal Group Sa sold 50,000 shares as the company’s stock rose 5.82% while stock markets declined. The institutional investor held 200,000 shares of the health care company at the end of 2017Q4, valued at $25.41M, down from 250,000 at the end of the previous reported quarter. Artal Group Sa who had been investing in Alnylam Pharmaceuticals Inc (Call) for a number of months, seems to be less bullish one the $10.05 billion market cap company. The stock increased 1.06% or $1.05 during the last trading session, reaching $100.02. About 100,098 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 150.73% since May 25, 2017 and is uptrending. It has outperformed by 139.18% the S&P500.

Artal Group Sa, which manages about $6.63B US Long portfolio, upped its stake in Accelerate Diagnostics Inc (NASDAQ:AXDX) by 300,000 shares to 500,000 shares, valued at $13.10M in 2017Q4, according to the filing. It also increased its holding in Medicines Co (Call) (NASDAQ:MDCO) by 500,000 shares in the quarter, for a total of 700,000 shares, and has risen its stake in Juno Therapeutics Inc (Call) (NASDAQ:JUNO).

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on August, 8. They expect $-1.71 earnings per share, down 27.61 % or $0.37 from last year’s $-1.34 per share. After $-1.41 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 21.28 % negative EPS growth.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Seekingalpha.com which released: “Wave Life Sciences: What’s Cooking Behind This Innovator?” on May 23, 2018, also Fool.com with their article: “Alnylam Looks Forward” published on May 08, 2018, Globenewswire.com published: “Consolidated Research: 2018 Summary Expectations for STORE Capital, Microvision, International Game Technology …” on May 11, 2018. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Fool.com and their article: “Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?” published on May 17, 2018 as well as Seekingalpha.com‘s news article titled: “Alnylam on go with late-stage study of lumasiran in PH1” with publication date: May 03, 2018.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Among 11 analysts covering Alnylam Pharma (NASDAQ:ALNY), 6 have Buy rating, 1 Sell and 4 Hold. Therefore 55% are positive. Alnylam Pharma had 23 analyst reports since December 11, 2017 according to SRatingsIntel. FBR Capital maintained it with “Buy” rating and $220.0 target in Monday, December 11 report. The firm has “Equal-Weight” rating given on Monday, May 7 by Morgan Stanley. FBR Capital maintained the shares of ALNY in report on Friday, January 19 with “Buy” rating. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by FBR Capital on Friday, February 16. Nomura maintained it with “Sell” rating and $86.0 target in Friday, February 9 report. FBR Capital maintained the stock with “Buy” rating in Monday, January 8 report. The rating was maintained by Jefferies with “Buy” on Monday, January 8. The rating was maintained by Stifel Nicolaus with “Hold” on Friday, May 4. JMP Securities maintained the stock with “Buy” rating in Tuesday, April 3 report. Credit Suisse maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Tuesday, March 13. Credit Suisse has “Outperform” rating and $154 target.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: